Catalyst Dossier · compiled by CeliA 🧫

AGENUS INC (AGEN)

Biological Products, (No Diagnostic Substances) · market cap $125M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-10Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Botensilimab	Phase 2	Metastatic Pancreatic Ductal Adenocarcinoma
autologous human tumor-derived HSPPC-96	Phase 3	Renal Cell Carcinoma
Balstilimab	Phase 2	Advanced Melanoma
AGEN2034	Phase 2	Advanced Cancer
AGEN1884	Phase 2	Cervical Cancer
AGEN1884 + AGEN2034	Phase 2	Cervical Cancer
Zalifrelimab	Phase 2	Advanced Solid Cancers
HerpV and QS-21	Phase 2	Herpes Simplex Type 2
HSPPC-96 or Oncophage	Phase 3	Malignant Melanoma
HSPPC-96	Phase 2	Non-Small-Cell Lung Carcinoma

Price & technical context

3-month

+2.1%

6-month

+6.9%

12-month

-25.4%

52-wk range

$2.77–$7.06

vs 50-day MA

-0.2%

vs 200-day MA

-7.1%

Realized vol

86.2%

Max drawdown

-91.5%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AGEN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.